Presbyopia in Breast Cancer Survivors
Chemotherapy drugs, used in cancer treatments, may change the timing of a vision condition known as presbyopia. Presbyopia is the inability to focus the eye on close objects, by a process called accommodation. It is caused by an increase in the stiffness of the lens of the eye that occurs naturally with aging. Currently, there are no known treatments that can be used to prevent or delay presbyopia. As a result, the risk, in later life, of having this condition is essentially 100%.
The purpose of this research is to determine whether chemotherapy drugs are delaying the age at which people develop symptoms of presbyopia. We hope to establish that presbyopia can in fact be delayed with the use of drugs, which would ultimately lead to further research in this area.
Description
Chemotherapy drugs, used in cancer treatments, may change the timing of a vision condition known as presbyopia. Presbyopia is the inability to focus the eye on close objects, by a process called accommodation. It is caused by an increase in the stiffness of the lens of the eye that occurs naturally with aging. Currently, there are no known treatments that can be used to prevent or delay presbyopia. As a result, the risk, in later life, of having this condition is essentially 100%.
The purpose of this research is to determine whether chemotherapy drugs are delaying the age at which people develop symptoms of presbyopia. We hope to establish that presbyopia can in fact be delayed with the use of drugs, which would ultimately lead to further research in this area.
Status: Withdrawn (N/A). Started on August 1st, 2005. Ended on May 1st, 2006.
Enrollment: 100 subjects
Study Type: Observational
Study Design:
- Retrospective
Conditions:
Interventions:
Eligibility
Inclusion Criteria:
ages 45-60
ability to understand and provide written consent in English
Exclusion Criteria:
visual defects leading to accomodative failure
severe myopia
recurrent breast cancer
- Gender
Both
- Mininum Age
45 Years
- Maximum Age
60 Years
- Healthy Volunteers
No
Resources
Source: Alberta Cancer Board
Authority: Canada: Health Canada
Locations
-
Alberta Cancer Board
Edmonton
Alberta
T6G 1Z2
Canada
-
Cross Cancer Institute
Edmonton
Alberta
T6G 1Z2
Canada
Officials
John Mackey, Dr. (Principal Investigator, Alberta Cancer Board)
Sponsors
Alberta Cancer Board (Lead Sponsor)
References
None.
Links
None.
- Date Verified
- July 1st, 2006
- First Received
- September 22nd, 2008
- Last Changed
- September 22nd, 2008
Information obtained from ClinicalTrials.gov on October 02, 2008. Link to the current ClinicalTrials.gov record.
All data in the Healia Clinical Trials Information Database and content displayed by the Healia Clinical Trials Search Engine are licensed from the National Institutes of Health (National Library of Medicine), which collects and maintains the data.
The Healia Clinical Trials Search Engine searches the data set at clinicaltrials.gov, providing up-to-date information about current clinical trials. In the Healia Clinical Trials Database you can find information on new experimental drugs, medical devices, and other types of treatments for all types of diseases. Each clinical trial description includes information about the phase of the trial (phase I, phase II, or phase III), the trial’s methods, such as whether it is a randomized, placebo controlled, double blind study, and the status of the trial including whether or not the trial is currently enrolling new participants.